ArticleBMC cancer2018
Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.Frontiers in pharmacology · 2019Pooled it
- Evaluation of the Accuracy and Reliability of Responses Generated by Artificial Intelligence Related to Clinical Pharmacology.Journal of clinical medicine · 2025Article
- Silent Killer in the Liver: A Rare Case of Primary Hepatic Angiosarcoma Presenting With Acute Liver Failure.Cureus · 2025Article
- A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2024Article
- Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver.Journal of immunotherapy and precision oncology · 2023Article
- Primary hepatic angiosarcoma with noncirrhotic portal hypertension: A case report.Frontiers in oncology · 2023Article
- Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review.World journal of clinical cases · 2022Article
- Surgical treatment outcomes of primary hepatic sarcomas: A single-center experience.World journal of hepatology · 2021Article
- Clinical characteristics of primary hepatic angiosarcoma outcomes: a SEER database analysis.Translational cancer research · 2021Article
- PD-1 mRNA expression in peripheral blood mononuclear cells as a biomarker for different stages of primary gouty arthritis.Journal of cellular and molecular medicine · 2020Article
- Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.Genome medicine · 2020Article
- Initial clinical radiological findings and staging to predict prognosis of primary hepatic angiosarcoma: A retrospective analysis.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPrimary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA. CASE PRESENTATION: A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15 months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor.
conclusionPazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.